Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HLA-DP0401/0402-restricted, MAGE-A3-reactive T cell receptor-transduced autologous T cells

Human autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-DP0401/0402-restricted, melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. CD4-positive cells are isolated from a patient, transduced with an anti-MAGE-A3-DP0401/0402 restricted TCR, expanded ex vivo, and reintroduced into the HLA-DP0401/0402 positive patient. Then, the HLA-DP0401/0402-restricted, MAGE-A3-reactive TCR-transduced autologous T cells bind to tumor cells expressing the MAGE-A3 antigen, which may result in both an inhibition of growth and increased cell death for MAGE-A3-expressing cancer cells. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-MAGE-A3-DP4 TCR PBL
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search